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Background and Aims: News strategies for the accurate assessment of the state of
immunosuppression (IS) in liver transplant recipients are needed to prevent rejection
and minimize drug-related side effects. miRNAs can potentially be used as diagnostic
or prognostic biomarkers in transplant patients. This study evaluated the capacity of a
plasmatic miRNA panel (miR-155-5p, miR-122-5p, miR-181a-5p, and miR148-3p) as
an early non-invasive prognostic and diagnostic biomarker for T cell-mediated acute
rejection (TCMAR) and subclinical rejection (SCR) in adult liver recipients.
Methods: A total of 145 liver recipients were included. All patients received a calcineurin
inhibitor with or without mycophenolate mofetil and methylprednisolone. Plasmatic
miRNA expression was assessed by qPCR before and at different time-points after
liver transplantation.
Results: Seventeen patients experienced TCMAR, and eight were diagnosed with SCR
during the protocol biopsy at the 3rd month post-transplantation. Pre-transplantation,
miR-155-5p expression was significantly higher in TCMAR patients and in SCR patients
than in non-rejectors, and miR-181a-5p expression was also significantly higher in
SCR patients than in non-rejectors. Post-transplantation, before transaminase-level
modification, significantly increased miR-181a-5p, miR-155-5p, and miR-122-5p
expression was observed in TCMAR and SCR patients. Binary logistic regression
analyses showed, post-transplantation, that TCMAR risk was better predicted by
individual expression of miR-181a-5p (LOGIT = −6.35 + 3.87∗miR-181a-5p), and
SCR risk was better predicted by the combination of miR-181a-5p and miR-155-5p
expression (LOGIT = −5.18 + 2.27∗miR-181a-5p+1.74∗miR-155-5p).
Conclusions: Pre-transplantation plasmatic miR-155-5p expression may be useful
for stratifying low-immunologic-risk patients, and post-transplantation miR-181a-5p
Millán et al. miRNA: Prognostic Biomarkers of Rejection
and miR-155-5p may be candidates for inclusion in early, non-invasive prognostic
biomarker panels to prevent TCMAR or SCR and better identify patient candidates for
IS minimization. Large prospective randomized multicenter trials are needed to refine the
cut-off values and algorithms and validate the clinical usefulness of these biomarkers.
Keywords: biomarkers, miR-181a-5p, miR-155-5p, liver transplantation, TCMAR, SCR
INTRODUCTION
Despite great advances in immunosuppressive (IS) therapy,
T cell-mediated rejection (TCMAR), which is the main form
of rejection in liver transplantation (LT), has an incidence
estimated ∼21–27% (1, 2). Moreover, the diagnosis of TCMAR
is based on the findings of liver biopsy, which is an invasive
procedure that can result in certain complications. On the
other hand, the side effects of IS therapy, such as increased
risk of renal failure and neoplasia or the impairment of
cardiovascular function, has led to strategies for IS reduction
to minimize these deleterious events. Accurate methods
for stratifying the net state of immune suppression are
lacking. The availability of non-invasive biomarkers of
an alloimmune response may provide physicians useful
information to better identify patients at high risk of rejection
and those who are good candidates for IS minimization
post-transplantation and to achieve more personalized
IS therapy. Monitoring these biomarkers may decrease
the requirement for the use of biopsies (3). Furthermore,
subclinical inflammatory lesions in the graft, such as portal
inflammation with variable grades of fibrosis as described
by Londoño et al. or histological signs of rejection without
biochemical abnormalities (subclinical rejection; SCR),
are less evaluated entities with uncertain significance and
prognosis (4–6).
Several studies have shown the potential role of miRNA
analysis as a non-invasive prognostic and diagnostic biomarker
of TCMAR (7). The control of gene expression by miRNAs
regulates many cellular functions, including differentiation,
proliferation, cellular development, and functional regulation
of the immune system, and miRNAs also participate in the
cellular mechanisms of inflammatory responses (8, 9). There is
evidence that miRNAs play an important role in post-transplant
clinical events, including rejection, disease recurrence, and the
development of tumors.
Publications on miRNAs in transplantation mostly focus on
the field of kidney transplantation (10–12). In LT, emerging
studies are evaluating the role of miRNA analysis as biomarkers
for liver injury. Hepatocyte-derived miRNAs, such as miR-122,
miR-148a, and miR-194, correlate with injury and acute rejection
Abbreviations: BPAR, biopsy-proven acute rejection; CsA, cyclosporine A; CI,
confidence interval; CMV, cytomegalovirus; CNi, calcineurin inhibitor; HCV,
hepatitis C virus; IS, immunosuppression; LT, liver transplantation; miRNA,
microRNA; MMF, mycophenolate mofetil; MPA, mycophenolic acid; NPV,
negative predictive value; PBMC, peripheral blood mononuclear cell; PPV, positive
predictive value; qPCR, quantitative real-time PCR; SCR, subclinical rejection;
ROC, receiver operating characteristic; TAC, tacrolimus; TCMAR, T cell-mediated
acute rejection; Th, T helper.
(AR). Serum levels of these miRNAs are increased in patients
with liver injury and positively correlate with aminotransferase
levels, but this increase occurs before aminotransferase levels are
modified during AR, showing the prognostic capacity of these
biomarkers (13). In fact, miR-122-5p is the most abundant liver-
derived miRNA, constituting 70% of the total miRNA in the liver
(14), and thus, a significant increase in this miRNA could be
associated with hepatocyte damage, toxicity, or viral infection
(15). Schmuck et al. also demonstrated that the levels of miR-
122-5p, miR-133a, miR-148a-3p, and miR-194 are significantly
higher in the bile of liver recipients who develop AR within the
first 6 months after transplantation and during the AR episode
(16). Recently, Shaked et al., by using the framework of the
Immune Tolerance Network Immunosuppression Withdrawal
(ITN030ST) and Clinical Trials in Organ Transplantation
(CTOT-03) studies, identified in plasma two miRNAs (miR-
483-3p and miR-885-5p) that, when combined together in
a signature, could diagnose and predict liver rejection with
high accuracy [area under the curve (AUC) = 89.5%; 95%
CI = 82–96%; sensitivity = 83.8%; specificity = 87.1%; positive
predictive value (PPV) = 72% and negative predictive value
(NPV)= 93%] (7).
Local inflammation associated with rejection is tightly
regulated by the different T helper (Th) subsets, such as Th1,
Th2, and Th17. The differentiation of CD4+T cells into these
different subsets is strongly influenced by cytokine signaling
and by the expression of subset-specific transcription factors,
such as miRNAs. Recently, it has been described that miR-
155-5p controls the differentiation of CD4+T cells into Th
cells (17, 18) and participates in the development of regulatory
T cells (19). It has been reported that miR-155-5p can also
act as a regulator of IFN-γ production in human T and NK
cells (17, 20). Previous results from multicenter studies have
shown that, in peripheral blood, intracellular T cell (CD4+
and CD8+ T cells) expression of IFN-γ correlates with graft
rejection and clinical outcome and could be a useful prognostic
and diagnostic biomarker in kidney and liver transplantation
(21, 22). Several groups have demonstrated that miR-155-5p is
overexpressed in renal allografts during acute cellular rejection
(10, 12). Recently, Blaya et al. (23) showed that miR-155-
5p expression is altered in both liver tissue and circulating
inflammatory cells (peripheral blood mononuclear cells) during
liver injury, thus regulating inflammatory cell recruitment and
liver damage. Another miRNA closely related to the function
of T lymphocytes is miR-181a. Li et al. demonstrated that
T cell receptor (TCR) sensitivity and signaling strength can be
modulated at the post-transcriptional level by miR-181a. The
recognition of donor antigens by recipient T cells in secondary
lymphoid organs initiates the adaptive inflammatory immune
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response leading to the rejection of allogeneic transplants.
Allospecific T cells become activated through the interaction of
their TCRs with an intact allogeneic major histocompatibility
complex; the modulation of selection also argues that this
miRNA might directly impact the mature T cell repertoire,
which might further affect the onset and/or progression of
the T cell alloresponse. miR-181a represents a novel class of
regulatory molecules that can modulate the T cell response.
Therefore, changes in its expression can regulate the alloresponse
against the implanted graft and, consequently, may play a
role in the development of rejection (24, 25). No data have
been reported regarding the potential utility of evaluating
plasmatic miRNA expression for predicting the risk of SCR in
LT recipients.
The aim of this study was to evaluate the capacity of a
plasmatic miRNA panel (miR-155-5p, miR-122-5p, miR-181a-
5p, and miR148-3p) as an early non-invasive prognostic and
diagnostic biomarker for TCMAR and (for the first time) for SCR
in adult LT recipients.
METHODS
Study Design and Patients
We conducted a prospective, observational study in a cohort of
145 adult patients undergoing LT in our center (Hospital Clínic
Barcelona). Combined liver-kidney recipients were excluded.
Only patients followed for at least 3 months after LT with plasma
samples collected were considered. The study was approved by
the Ethics Committees of the center, and all patients provided
their written informed consent.
Patient Follow Up and Immunosuppressant
Regimens
All LT recipients were managed by transplant hepatologists
according to standardized protocols throughout the follow up.
After discharge after transplantation, the patients visited the
outpatient clinic monthly for the first 3 months and every 2
months thereafter during the first year. Clinical, demographical
and laboratory data of the patients were collected. IS regimens
were defined by the pre-transplant liver status according to the
Child-Pugh classification. Child-Pugh A patients were given a
double IS therapy consisting of tacrolimus (TAC) or cyclosporine
(CsA) with target trough levels of 8–10 or 150–300 ng/ml,
respectively, plus a tapering dose of corticosteroids to be
withdrawn at 6 months after LT. Child-Pugh B and C patients,
those transplanted due to acute liver failure and retransplanted
patients who received induction therapy with a single dose of
basiliximab immediately after LT, delayed the start (5th day) of
TAC or CsA with target trough levels of 5–8 or 75–150 ng/ml,
respectively, mycophenolate mofetil (MMF) 2,000mg daily, and
a tapering dose of corticosteroids to be withdrawn at 6 months
after LT. A low dose of corticosteroids (prednisone 2.5–5mg) was
maintained long-term in those patients transplanted due to an
autoimmune disease.
Liver Biopsies and Rejection Episodes
Liver biopsies were performed if clinically indicated and if the
following criteria were met: aspartate aminotransferase, alanine
aminotransferase, alkaline phosphatase or direct bilirubin serum
levels higher than 2-fold the upper limit of normal and absence of
pathological findings in the abdominal ultrasound examination
that could explain these biochemical abnormalities. All rejection
episodes were biopsy proven, and severity was defined by the
Rejection Activity Index (RAI) Score (26, 27). Moderate (RAI
5–6) and severe (RAI > 6) episodes were treated with steroid
boluses (500mg of methylprednisolone for three consecutive
days), while mild episodes (RAI 3–4) were treated by increasing
the dose and levels of current immunosuppressants. In addition,
a per-protocol biopsy was performed at month 3 after LT
in all patients in whom a clinically indicated biopsy had not
been performed, unless there was a clinical contraindication
(mainly, biliary complications). All these patients submitted
to a per-protocol biopsy and had normal liver function tests
and abdominal ultrasound examination. If histological signs of
TCMAR were found, patients were diagnosed with subclinical
rejection (SCR). No additional treatment was given for this event,
but IS doses were maintained without minimization for at least 4
weeks after biopsy.
Pharmacokinetic Monitoring
Therapeutic drug monitoring of CNi was performed in
the Laboratory of Pharmacology. For each CNi, the trough
concentration at the 1st week, on the 15th day, and at the 1st,
2nd, 3rd, 6th, 9th, and 12th month post-transplantation were
analyzed. Whole blood TAC concentrations were determined
by Tacrolimus-CMIA-Architect from Abbot (Wiesbaden,
Germany), and whole blood CsA concentrations were measured
by Cyclosporin-ACMIA-Dimension from Siemens (Siemens
Healthcare Diagnostic, Deerfield, IL, USA) following the
manufacturer’s instructions. Fresh samples, without having
been previously frozen, were analyzed daily. LGC Standard
Proficiency Testing was ensured by the participation of our
laboratory in the United Kingdom External Analytical Quality
Assessment Service.
Plasma miRNA Analysis
At the same time as the clinical visits and pharmacokinetic
profiles, plasma miR-155-5p, miR-122-5p, miR-181a-5p, and
miR-148-3p expression was assessed by quantitative real-time
PCR (qPCR). We selected these miRNAs based on the results
of previous studies that showed them as promising biomarkers
in the diagnosis and prognosis of rejection and for their
involvement in the response mechanisms that the immune
system performs against the graft. A total of 4,785 determinations
were performed: 1,305 determinations for each miR evaluated
(145 patients, 9 visits, and 3 miRs), except for miR-148-3p, which
had 870 determinations, because the follow up was performed
until 3 months post-transplantation (145 patients, 6 visits, 1
miR). Blood samples (3ml) were collected into EDTA-K3 tubes
at the pre-transplantation visit and at each post-transplantation
visit according to the study design. Blood samples were obtained
prior to the immunosuppressant administration (pre-dose); at
those points concurrent with rejection episodes, the samples
were collected before any treatment change was made. After
centrifugation (within 2 h) at 3,000 rpm for 10min, plasma
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was collected and stored in RNase-free tubes at −70◦C for
batched analysis.
Total RNA was purified from 200 µL of patient plasma
according to the manufacturer’s instructions [miRCURYTM
RNA Isolation Kits – Biofluids ref. #300112 from EXIQON
(Denmark)]. Briefly, plasma components were lysed with the
provided Lysis Solution, and proteins were precipitated with
the provided Protein Precipitation Solution. Isopropanol was
added to the collected supernatant, and the solution was loaded
into the column. The solution was washed with Wash Solutions
1 and 2, the RNA was eluted with RNase-free water, and the
concentration and quantity of the total RNA were measured
at 260 nm and 280 nm (A260/A280) using a NanoDrop device
(NanoDrop Technologies). Hemolysis contamination was tested
using a spectrophotometer and measuring the oxyhemoglobin
absorbance at 414 nm. An OD scan was performed from ∼200
to 700 nm, and distinguishing absorbance peaks at 414 nm
were used to disqualify hemolysis samples. Total RNA was
reverse transcribed into cDNA following the manufacturer’s
instructions (miRCURY LNATM Universal RT ref #203301 from
EXIQON). cDNA served as a template for miRNA RT-qPCR
amplification with locked nucleic acid (LNA) primers and SYBR
Green master mix. The following specific LNA PCR primer
sets, all from EXIQON (Denmark), were used: hsa-miR-155-5p
LNATM PCR primer set, UniRT (ref.# 204308); hsa-miR-181a-
5p LNATM PCR primer set, UniRT (ref. # 206081); hsa-miR-
122- 5p LNATM PCR primer set, UniRT (ref, # 205664); hsa-
miR-148a-3p LNATM PCR primer set, UniRT (ref.# 205867);
hsa-miR-103a-3p, LNATM PCR primer set, UniRT (ref. 204063);
and hsa-miR-191-5p, LNATM PCR primer set, UniRT (ref. #
204306). To monitor the cDNA synthesis reaction, the synthetic
spike-in UniSP6 was used for signs of inhibition (prior to the
reverse transcription reaction, we added 1 µl of synthetic spike-
in (108 copies/µl) per 20 ng sample RNA). PCRs were performed
using a Light Cycler 480 instrument. The amplification profile
was denatured at 95◦C for 10min followed by 45 amplification
cycles of 95◦C for 10 s and 60◦C for 1min. At the end of the
PCR cycles, melting curve analyses were performed. Negative
controls with 1 µg of MS2 carrier RNA as a mock template
from the reverse transcription reaction were produced and
profiled similarly to the samples. The amplification curves were
analyzed using Roche LC Software for determination of Cq by the
second derivative method. Average Cq values were normalized
to the stably expressed reference miR-103a-3p and miR-191-5p,
following the manufacturer’s instructions. First, the Cq values
for all samples were determined; the average Cq of miR-191-
5p + miR-103-3p was calculated, and the 1Cq was calculated
as the difference in Cq values between the miRNA target and
the reference control (Cq average of miR-191-5p+miR-103-5p).
Relative expression levels of target miRNAs were then evaluated
within a sample according to the formula 2∧(-1Cq), where high
values corresponded to higher expression.
Statistical Analyses
Demographic data and results of the molecular analyses were
collected in a unified database. Samples were adjusted to a non-
parametric distribution. Statistical differences between groups
were assessed with the Mann–Whitney test and Kruskal–Wallis
test, and correlations between miRNA expression and clinical
events were assessed with Spearman’s rho test. We used a
receiver operating characteristic (ROC) curve analysis to define
the optimal cut-offs for differentiating between patient groups
with and without TCMAR or SCR. Optimal biomarker cut-
off points to discriminate between patients with and without
TCMAR were based on ROC curves and calculated with the best
Youden index (28) (sensitivity + specificity−1). For the analysis
of SCR, we treated the data of this group as an independent
group during the evaluation period. Discriminatory capacity
was defined by the AUC (0.7–0.8, acceptable; 0.8–0.9, excellent;
>0.9, outstanding), with its 95% confidence interval (CI). All
analyses were performed using SPSS 23.0 software (SPSS, Inc.,
Chicago, IL, USA). All data are presented as the median ±
standard deviation (SD). A value of P ≤ 0.05 was considered
statistically significant. To better evaluate not only the diagnostic
capacity of the biomarkers evaluated in this study but also their
prognostic utility, we included in the TCMAR box-plot data
from patients who exhibited rejection at this time plus the pre-
TCMAR data of the patients who had not yet exhibited rejection
at this time but who would do so in a later profile. We did not
consider data from rejector patients once the TCMAR episode
was resolved in the TCMAR box-plot graph. A binary logistic
regression model (26) was performed using NONMEM software
[version 7.4.1; Icon development Solutions, Ellicott City, MD,
USA; (29)] with the Laplacian first order conditional estimation
method. TCMAR and SCR occurrence were evaluated as binary
data and used as response variables (RVs), with 0 indicating no
event, and 1 indicating occurrence of the event. As explanatory
variables, miR-155-5p and miR-181a-5p plasmatic expression
were used. The probability of the observed score was linked to
explanatory variables through the logit transformation to ensure
that the estimated probability fell between 0 and 1. Graphic
evaluation of the output was performed with R software (30). As
a model evaluation, a visual predictive check (vpc) after 1,000
simulations using vpc R package (31) and a bootstrap analysis




From September 2014 to July 2018, 178 patients were included.
Twelve patients remained on the LT waiting list at the end
of the inclusion period, 6 died before undergoing LT, and 15
patients did not met the minimum follow-up period for several
reasons: 5 died before month 3; 1 transplant could not be
performed because of a technical impossibility found during
surgery; 4 patients withdrew consent; and 5 had no complications
but a shorter than 3-month follow up at the time of analysis.
The final study cohort consisted of 145 individuals. The main
characteristics are shown in Table 1. Most patients were males
(72.4%), with a mean age of 56.5 years. The main etiologies of
primary liver disease were HCV and alcohol, and hepatocellular
carcinoma was the indication for LT in 47.6% of patients. The
majority of donors were donors after brain death, with a median
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Sex (male) 105 (72.4%) 89 (74.2%) 12 (70.6%) 4 (50%) 0.35
Recipient age (years) 56.5 ± 8.6 58.5 ± 8.5 51.0 ± 9.6 57.0 ± 7.9 0.74
Primary disease Alcohol 34 (23.5%) 27 (22.5%) 5 (29.4%) 2 (25%) 0.50
HCV 44 (30.3%) 38 (31.7%) 4 (23.5) 2 (25%)
HCV + Alcohol 9 (6.2%) 8 (6.7%) 1 (5.9%) 0
HBV 10 (6.9%) 10 (8.3%) 0 0
Autoimmune 6 (4.1%) 4 (3.3%) 0 2 (25%)
PBC 10 (6.9%) 7 (5.8%) 2 (11.8%) 1 (12.5%)
PSC 4 (2.8%) 3 (2.5%) 1 (5.9%) 0
Cryptogenic 7 (4.8%) 5 (4.2%) 1 (5.9%) 1 (12.5%)
NASH 11 (7.6%) 9 (7.5%) 2 (11.8%) 0
Other 10 (6.9%) 9 (7.5%) 1 (5.9%) 0
Hepatocellular carcinoma 69 (47.6%) 58 (47.9%) 7 (42.8%) 4 (50%) 0.94
Donor age (years) 58.5 ± 14.4 58.6 ± 15.5 53.0 ± 15.3 68.5 ± 8.4 0.22
Cold ischemia time (minutes) 460.6 ± 146 443.5 ± 133.8 430 ± 112.2 515.0 ± 133.8 0.65
Type of donor Living donor 1 (0.7%) 1 (0.8%) 0 0 0.61
DBD 123 (84.8%) 103 (85.8%) 14 (82.4%) 6 (75%)
DCD 21 (14.5%) 16 (13.4%) 3 (17.6%) 2 (25%)
Immunosuppressive regimen TAC + PDN 61 (42.1%) 49 (40.8%) 8 (47.1%) 4 (50%) 0.45
TAC + MMF + PDN 54 (37.2%) 43 (35.8%) 8 (47.1%) 3 (37.5%)
CsA + PDN 15 (10.3%) 14 (11.7%) 0 1 (12.5%)
CsA + MMF + PDN 15 (10.3%) 14 (11.7%) 1 (5.8%) 0
Post-transplant infections HCV 8 (5.5%) 8 (6.7%) 0 0 0.59
CMV 41 (28.3%) 34 (28.3%) 4 (23.5%) 3 (37.5%) 0.62
Bacterial 48 (33.1%) 35 (29.2%) 8 (47.1%) 5 (62.5%) 0.07
Quantitative variables are displayed with median and standard deviation. Count variables are displayed raw and intragroup relative frequency. HCV, Hepatitis C Virus; HBV, Hepatitis B
Virus; PBC, Primary Biliary Cholangitis; PSC, Primary Sclerosing Cholangitis; NASH, Non-Alcoholic Steatohepatitis; DBD, Donor after Brain Death; DCD, Donor after Cardiac Death;
TAC, Tacrolimus; PDN, Prednisone; MMF, Mycophenolate Mofetil; CsA, Cyclosporine A; CMV, Cytomegalovirus.
age of 58.5 years. Regarding the immunosuppressive regimen,
79.3% of patients received TAC (with or without MMF), while
the remaining 20.7% had cyclosporine A. Among patients with
HCV as primary disease (n = 53), 8 of them were positive for
HCV RNA at the time of transplant. As expected, all of them had
HCV recurrence after LT.
Rejection Episodes
Eighteen episodes of TCMAR were diagnosed in 17 patients
(one patient had two events). Regarding the severity, 9 were
moderate, and 9 were mild. With respect to the timing, three
episodes of TCMAR were diagnosed during the first week post-
transplantation, six during the second week, four at the end
of month 1, one at month 3, two at month 6, and two at
month 12. All of these episodes were recovered with therapy,
and no graft was lost due to rejection. Eight patients were
diagnosed with SCR at the time of the per-protocol biopsy.
Only one of these eight patients developed clinical TCMAR,
after the follow-up period expired. As reflected in Table 1, no
significant differences were found in the main characteristics
of the cohort when comparing those patients who did not
develop rejection, patients who presented TCMAR and those
with SCR.
Pharmacokinetics
Trough concentrations for TAC and CsA, and MPA and
prednisone doses are summarized in Table 2. No statistically
significant differences between rejectors (TCMAR or patients
with SCR) and non-rejectors were observed in trough
concentrations for TAC or CsA neither in MPA or prednisone
doses during the period evaluated.
miRNA Expression and TCMAR
Pre-transplantation, no significant differences were observed
in the plasmatic expression of miR-122-5p, miR-181a-5p, and
miR-148-3p between patients who suffered a TCMAR rejection
episode after transplantation from those patients who were
free of rejection (Figures 1B–D). Only the pre-transplantation
differences between both groups achieved significance for the
expression of miR-155-5p (P < 0.001) (Figure 1A).
Post-transplantation, a significant increase in the expression
of miR-155-5p, miR-122-5p, and miR-181a-5p was observed
Frontiers in Immunology | www.frontiersin.org 5 April 2019 | Volume 10 | Article 873
Millán et al. miRNA: Prognostic Biomarkers of Rejection
TABLE 2 | Pharmacokinetics parameters.
No AR (120) TCMAR (n = 17) SCR (n = 8) No AR vs. TCMAR No AR vs. SCR TCMAR vs. SCR
1st Week 1st Week 1st Week P value P value P value
TAC dose (mg/day) 4.0 ± 2.3 4.5 ± 2.1 5.0 ± 2.0 0.739 0.793 0.889
Cmin TAC (ng/mL) 5.5 ± 3.5 5.0 ± 3.4 6.0 ± 2.4 0.779 0.894 0.961
CsA dose (mg/day) 300.0 ± 142.1 650.0 ± 212.1 500.0 ± 125.3 0.059 0.333 0.667
Cmin CsA (ng/mL) 177.0 ± 83.9 105.6 ± 67.1 125.3 ± 56.4 0.134 0.083 0.500
Prednisone (mg/day) 20 ± 4.1 20 ± 4.3 20 ± 6.5 0.753 0.398 0.448
MPA dose (mg/day) 2000 ± 468.1 2000 ± 333.3 2000 ± 250.5 0.424 0.616 0.909
No AR (123) TCMAR (n = 14) SCR (n = 8) No AR vs. TCMAR No AR vs. SCR TCMAR vs. SCR
Day 15th Day 15th Day 15th P-value P-value P-value
TAC dose (mg/day) 6.0 ± 2.9 7.0 ± 1.9 5.5 ± 1.8 0.661 0.703 0.571
Cmin TAC (ng/mL) 5.8 ± 2.3 4.9 ± 1.5 5.2 ± 1.9 0.339 0.811 0.827
CsA dose (mg/day) 400.0 ± 110.7 500.0 ± 141.4 395.0 ± 105.2 0.333 0.500 0.667
Cmin CsA (ng/mL) 144.0 ± 91.2 186.3 ± 10.9 150.2 ± 11.5 0.436 0.200 0.667
Prednisone (mg/day) 20 ± 1.1 20 ± 1.0 20 ± 0.5 0.843 0.919 1.000
MPA dose (mg/day) 2000 ± 522.4 2000 ± 408.2 2000 ± 350.5 0.733 0.589 0.857
No AR (129) TCMAR (n = 8) SCR (n = 8) No AR vs. TCMAR No AR vs. SCR TCMAR vs. SCR
1st Month 1st Month 1st Month P-value P-value P-value
TAC dose (mg/day) 8.0 ± 2.8 4.0 ± 2.9 4.5 ± 0.7 0.030 0.045 0.800
Cmin TAC (ng/mL) 7.1 ± 2.4 5.5 ± 2.3 6.6 ± 1.9 0.608 0.833 0.573
CsA dose (mg/day) 300.0 ± 122.4 400.0 ± 120.2 300. ± 1.77.2 0.600 0.400 0.317
Cmin CsA (ng/mL) 194.2 ± 109.2 238.6 ± 65.5 225.5 ± 56.3 0.870 0.273 0.667
Prednisone (mg/day) 20 ± 2.3 20 ± 2.2 20 ± 2.5 0.957 0.913 0.905
MPA dose (mg/day) 2000 ± 543.3 2000 ± 520.3 2000 ± 495.6 0.246 0.246 0.958
No AR (133) TCMAR (n = 4) SCR (n = 8) No AR vs. TCMAR No AR vs. SCR TCMAR vs. SCR
2nd Month 2nd Month 2nd Month P-value P-value P-value
TAC dose (mg/day) 6.0 ± 2.9 4.0 ± 1.9 4.5 ± 2.1 0.130 0.104 0.48
Cmin TAC (ng/mL) 7.3 ± 2.8 5.2 ± 2.0 6.6 ± 2.5 0.133 0.213 0.221
CsA dose (mg/day) 200.0 ± 98.5 400 ± 135.2 150.0 ± 95.6 0.308 0.462 0.317
Cmin CsA (ng/mL) 184.0 ± 53.3 310.9 ± 98.5 165.2 ± 44.6 0.143 0.714 0.321
Prednisone (mg/day) 15 ± 4.4 12.5 ± 3.5 15 ± 4.1 0.459 0.946 0.533
MPA dose (mg/day) 1500 ± 535.9 2000 ± 126.3 2000 ± 545.6 0.216 0.216 0.901
No AR (133) TCMAR (n = 4) SCR (n = 8) No AR vs. TCMAR No AR vs. SCR TCMAR vs. SCR
3rd Month 3rd Month 3rd Month P-value P-value P-value
TAC dose (mg/day) 7.0 ± 3.1 5.9 ± 2.3 5.0 ± 2.2 0.157 0.549 0.317
Cmin TAC (ng/mL) 7.6 ± 2.9 7.5 ± 3.9 5.8 ± 1.5 0.978 0.046 0.329
CsA dose (mg/day) 247.0 ± 98.5 250 ± 78.5 150.0 ± 89.5 0.364 0.364 0.966
Cmin CsA (ng/mL) 184.5 ± 56.6 239.1 ± 113.8 177.5 ± 54.2 0.032 0.909 0.667
Prednisone (mg/day) 10 ± 4.5 7.5 ± 3.5 10 ± 5.0 0.288 0.191 0.200
MPA dose (mg/day) 1000 ± 494.5 2000 ± 175.5 2000 ± 495.5 0.062 0.055 0.933
No AR (134) TCMAR (n = 3) SCR (n = 8) No AR vs. TCMAR No AR vs. SCR TCMAR vs. SCR
6th Month 6th Month 6th Month P-value P-value P-value
TAC dose (mg/day) 5.0 ± 2.7 4.5 ± 2.3 5.0 ± 2.1 0.444 0.810 0.756
Cmin TAC (ng/mL) 7.5 ± 2.2 8.5 ± 5.7 6.5 ± 2.0 0.752 0.326 0.982
CsA dose (mg/day) 250.0 ± 58.5 300 ± 0 150.0 ± 75.9 0.126 0.200 0.317
Cmin CsA (ng/mL) 149.0 ± 53.1 185.5 ± 0 173.4 ± 61.5 0.800 0.827 0.735
Prednisone (mg/day) 5 ± 3.8 3.5 ± 1.5 5 ± 4.5 0.165 0.209 0.500
MPA dose (mg/day) 1000 ± 378.2 Ø 1500 ± 288.6 Ø 0.125 Ø
(Continued)
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TABLE 2 | Continued
No AR (135) TCMAR (n = 2) SCR (n = 8) No AR vs. TCMAR No AR vs. SCR TCMAR vs. SCR
9th Month 9th Month 9th Month P-value P-value P-value
TAC dose (mg/day) 5.0 ± 2.1 3.0 ± 0 4.0 ± 2.6 0.069 0.089 0.835
Cmin TAC (ng/mL) 7.5 ± 1.9 7.7 ± 0 8.3 ± 0.9 0.966 0.422 0.655
CsA dose (mg/day) 200 ± 46.9 200 ± 0 155.0 ± 65.5 0.985 0.250 0.715
Cmin CsA (ng/mL) 137.0 ± 40.63 170.2 ± 0 163.4 ± 69.6 0.525 0.126 0.791
Prednisone (mg/day) 5 ± 4.3 5 ± 2.5 5 ± 2.5 0.647 0.724 0.800
MPA dose (mg/day) 720 ± 422.9 Ø 1000 ± 288.7 Ø 0.178 Ø
No AR (135) TCMAR (n = 2) SCR (n = 8) No AR vs. TCMAR No AR vs. SCR TCMAR vs. SCR
12th Month 12th Month 12th Month P-value P-value P-value
TAC dose (mg/day) 5.0 ± 2.1 3.0 ± 0 3.8 ± 0.4 0.375 0.273 0.667
Cmin TAC (ng/mL) 6.7 ± 2.4 12.3 ± 0 6.0 ± 2.2 0.125 0.742 0.221
CsA dose (mg/day) 200.0 ± 77.3 200 ± 0 150.0 ± 48.6 0.958 0.526 0.712
Cmin CsA (ng/mL) 144 ± 30.3 104.2 ± 0 179.5 ± 32.5 0.750 0.325 0.625
Prednisone (mg/day) 0 0 0 0.667 0.886 0.500
MPA dose (mg/day) 860 ± 190.4 Ø 1000 ± 250.3 Ø 0.727 Ø
Bold value of P ≤ 0.05 was considered significant.
in rejector patients compared with that in non-rejector
patients (Figures 1A–C); however, no significant differences were
observed in the plasmatic expression of miR-148-3p (Figure 1D).
Cut-off values for prognostic TCMAR were determined based
on the AUC of the ROC curve analysis for each miRNA, with
significantly higher levels in patients who showed rejection
(TCMAR). ROC curve analysis showed that pre-transplantation,
miR-155-5p had an outstanding capacity to discriminate between
rejectors and non-rejectors (AUC = 0.921; 95% CI = 0.861–
0.981) (Figure 2A). The optimal cut-off value for prognostic
TCMAR based on the AUC of the ROC curve for miR-155-5p
was 0.075, with 93% sensitivity, 82% specificity, 56.6% PPV, and
100% NPV (Supplementary Table 1).
Post-transplantation, ROC curve analysis showed that miR-
155-5p, miRNA-122-5p, and miRNA-181a-5p also showed an
outstanding capacity to discriminate between rejectors and non-
rejectors: miRNA-155-5p, AUC= 0.940 (95% CI= 0.889–0.992),
an optimal cut-off value to prognostic TCMAR of 0.463 with
a 91% sensitivity, 95% specificity, 95% PPV, and 99% NPV
(Figure 2B); miR-122-5p, AUC= 0.978 (95% CI= 0.966–0.990),
an optimal cut-off value to prognostic TCMAR of 4.356 with
a 93% sensitivity, 90% specificity, 71% PPV, and 98% NPV
(Figure 2C); and miR-181a-5p, AUC = 0.953 (95% CI = 0.913–
0.992), an optimal cut-off value to prognostic TCMAR of 0.760
with a 90% sensitivity, 95% specificity, 90% PPV, and 97% NPV
(Figure 2D). In contrast, miR-148-3p showed a low capacity to
discriminate between rejectors and non-rejectors (AUC = 0.686;
95% CI= 0.612–0.761) (Figure 2E) (Supplementary Table 1).
The results of an analysis of the individual evolution in
the expression of miR-155-5p, miR-122-5p, and miR-181a-
5p in each rejector patient prior to, during and after the
TCMAR episodes showed that the expression of each miRNA
progressively increased preceding the TCMAR episode and
reached maximum levels at the time of the episode. Once
the immunosuppressive treatment was modified to resolve
the TCMAR episode, the miRNA levels decreased (Figure 3).
Comparing the miRNA expression evolution with the evolution
of serum aminotransferase levels, and taking into account
that aminotransferase levels were not normalized until 1–2
weeks post-surgery, in patients who exhibited rejection after 15
days of transplantation (8 of 17 patients), the increase in the
plasmatic miR-155-5p, miR-122-5p, andmiR-181a-5p expression
occurred before aminotransferase levels were modified during
TCMAR. Specifically, in patients who showed rejection at 3,
6, or 12 months post-transplantation, these miRNAs levels
were above the cut-off value for the risk of rejection in
the first weeks post-transplantation, and their increase was
earlier and more rapid than the serum levels of aspartate
aminotransferase (AST), alanine aminotransferase (ALT), and
gamma-glutamyl-transpeptidase (GGT), which usually took
place 2–3 weeks before rejection occurred. Furthermore, no
significant differences were observed in the evolution of the
serum aminotransferase levels between non-rejectors, TCMAR
and SCR patients (Supplementary Table 2).
miRNA Expression and SCR
Pre-transplantation differences between non-rejectors and
patients who were diagnosed with SCR after transplantation
achieved significance for the expression of miR-155-5p
(P < 0.001) (Figure 1A) and miRNA-181a-5p (P = 0.012)
(Figure 1C); however, no significant differences were
observed in the plasmatic expression of miR-122-5p
and miR-148-3p between SCR patients and those free of
rejection (Figures 1B,D).
Post-transplantation, a significant increase in the expression
of miR-155-5p, miR-122-5p, and miR-181a-5p was observed
in patients with SCR compared with that in non-rejector
patients (Figures 1A–C); however, no significant differences were
observed in the plasmatic expression of miR-148-3p (Figure 1D).
Cut-off values to prognostic SCR were also determined
based on the AUC of the ROC curve analysis for each
miRNA, with significantly higher levels in patients with SCR
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FIGURE 1 | Correlation of pre- and post-transplantation plasmatic miRNA expression with acute rejection (TCMAR) and subclinical rejection (SCR). Differences
between TCMAR patients (white boxes), non-rejectors (gray boxes) and subclinical rejectors (gray hatched boxes) with respect to miR-155-5p (A), miR-122-5p (B),
miR-181a-5p (C), and miR-148-3p expression (D), over 1 year post-transplantation. Seventeen of the 145 patients experienced TCMAR episodes (3 episodes
occurred during the 1st week post-transplantation, 6 at day 15th, 4 at the end of the 1st month, 1 during the 3rd month, 1 during the 6th month, and 2 during the
12th month post-transplantation). Eight patients were diagnosed with SCR and were considered an independent group. TCMAR box-plots include data from the
patients who exhibited rejection at this time plus the pre-TCMAR data of the patients who had not yet exhibited rejected at this time but who would do so in a later
profile. Therefore, the number of samples that contributed to the data for both groups in each profile is as follows: non-rejectors: pre-transplantation n = 120; 1st
week n = 120; 15th day n = 123; 1st month n = 129; 2nd month n = 133; 3rd month n = 133; 6th month n = 134; 9th month n = 135 and 12th month n = 135 vs.
TCMAR rejectors pre-transplantation n = 17; 1st week n = 17; 15th day n = 14; 1st month n = 8; 2nd month n = 4; 3rd month n = 4; 6th month n = 3; 9th month
n = 2 and 12th month n = 2. *Indicates significant differences between TCMAR and non-rejectors; †Indicates significant differences between SCR and non-rejectors;
and ‡Indicates significant differences between TCMAR and patients with SCR. The solid horizontal line indicates the post-transplantation cut-off value (0.453) for
miR-155-5p expression (A), the post-transplantation cut-off value (4.356) for miR-122-5p expression (B), the post-transplantation cut-off value (0.760) for
miR-181a-5p expression (C).
(Figure 4). Pretransplantation, miR-155-5p had an outstanding
capacity to discriminate between SCR patients and non-rejectors
(AUC= 0.942; 95% CI= 0.886–0.999) (Figure 4A). The optimal
cut-off value to prognostic SCR based on the AUC of the ROC
curve for miR-155-5p was 0.060, with 100% sensitivity, 75.3%
specificity, 57% PPV, and 100% NPV. For miR-181a-5p, the
results showed an excellent capacity to discriminate between SCR
patients and non-rejectors (AUC = 0.826; 95% CI = 0.640–
1.000) (Figure 4B). The optimal cut-off value to prognostic SCR
based on the AUC of the ROC curve for miR-181a-5p was
0.457, with 80% sensitivity, 87.7% specificity, 53% PPV, and 100%
NPV (Supplementary Table 1).
Frontiers in Immunology | www.frontiersin.org 8 April 2019 | Volume 10 | Article 873
Millán et al. miRNA: Prognostic Biomarkers of Rejection
FIGURE 2 | ROC curve analysis for discrimination between rejectors (TCMAR) and non-rejectors. ROC curve analysis for discrimination between rejectors (TCMAR)
and non-rejectors for each miRNA was evaluated. (A) Pre-transplantation miR-155-5p capacity to discriminate between rejectors and non-rejectors (AUC = 0.921;
95% CI = 0.861–0.981; cut-off value = 0.075 [93% sensitivity, 82% specificity, PPV = 56.6% and NPV = 100%)]; (B–E) Post-transplantation miRNA capacity to
discriminate between rejectors and non-rejectors: (B) miRNA-155-5p AUC = 0.940 (95% CI = 0.889–0.992) and cut-off value = 0.463 (91% sensitivity, 95%
specificity, PPV = 95% and NPV = 99.8%); (C) miR-122-5p AUC = 0.978 (95% CI = 0.966–0.990) and cut-off value = 4.356 (93% sensitivity, 90% specificity,
PPV = 71% and NPV = 98%); (D) miRNA-181a-5p AUC = 0.953 (95% CI = 0.913–0.992) and cut-off value = 0.760 (90% sensitivity, 95% specificity, PPV = 90%
and NPV = 97%); (E) miRNA-148-3p AUC = 0.686 (95% CI = 0.612–0.761).
Post-transplantation, ROC curve analysis showed that miR-
155-5p, miR-122-5p, and miR-181a-5p also had an outstanding
capacity to discriminate between SCR patients and non-rejectors:
miR-155-5p, AUC = 0.977 (95% CI = 0.962–0.991), an optimal
cut-off value to prognostic SCR of 0.255 with a 93.3% sensitivity,
90% specificity, 89% PPV, and 100% NPV (Figure 4C); miR-
122-5p, AUC = 0.921 (95% CI = 0.874–0.967), an optimal cut-
off value to prognostic SCR of 2.726 with an 84% sensitivity,
80% specificity, 75% PPV, and 90% NPV (Figure 4D); and miR-
181a-5p, AUC = 0.949 (95% CI = 0.910–0.988), an optimal
cut-off value to prognostic SCR of 0.587 with a 91% sensitivity,
88% specificity, 91% PPV, and 90% NPV (Figure 4E). miR-
148-3p also showed a low capacity to discriminate between
both groups of patients (AUC = 0.592; 95% CI = 0.505–0.678)
(Figure 4F) (Supplementary Table 1).
In patients diagnosed with SCR during the protocol
biopsy, the expression of each miRNA (miR-155-5p, miR-
122-5p, and miR-181a-5p) also progressively increased, from
pre-transplantation to the 3rd month post-transplantation, and
it remained above the cut-off value for the risk of TCMAR
during all periods of the study (1 year post-transplantation)
(Figure 5). Instead, in all of these patients, after the 1st week
post-transplantation, the serum transaminase levels remained
within normal range. One of these patients (Patient #5) finally
showed rejection at the 13th month post-transplantation, for
which we obtained a sample to evaluate miRNA expression
(Figure 5). While their miRNA levels were already elevated after
the immediate post-transplant period, their transaminase values
did not increase until 3 weeks before the TCMAR occurred.
miRNA Expression in Patients With SCR
and TCMAR
Between rejectors (TCMAR) and patients with SCR, differences
in the expression of miR-155-5p were significantly increased
in TCMAR until the 2nd month post-transplantation, after
Frontiers in Immunology | www.frontiersin.org 9 April 2019 | Volume 10 | Article 873
Millán et al. miRNA: Prognostic Biomarkers of Rejection
FIGURE 3 | Evolution of miR-155-5p, miR-122-5p, and miR-181a-5p expression in patients experiencing TCMAR. An example of the evolution of the miR-155-5p,
miR-122-5p, and miR-181a-5p expression in two rejector patient prior to, during and after the TCMAR episodes. The arrow indicates the time of the TCMAR episode.
which no significant differences were observed in either group
(Figure 1A). For miR-122-5p expression, except in the 1st week
post-transplantation, no differences were observed in either
group (Figure 1B). Additionally, for miR-181a-5p after the 3rd
month post-transplantation, SCR patients showed an increase
in expression compared with the TCMAR group, and these
differences disappeared 1 year post-transplantation (Figure 1C).
Development and Validation of a
Prognostic Algorithm for the Risk of
TCMAR and SCR Based on miR-155-5p
and miR-181a-5p Expression
A binary logistic regression model was performed to assess the
prognostic capacity of the risk of TCMAR or SCR events based
on the expression of miR-155-5p and miR-181a-5p individually
or in combination as explanatory variables.
The results showed that TCMAR risk was better predicted
by the individual expression of miR-181a-5p than by miR-155-
5p alone or both miRNAs in combination. Concerning SCR
risk prediction, the model that considers a combination of both
miRNAs showed a high capacity to prognostic this clinical event.
Bootstrap analysis, after 1,000 resamplings, and a vpc, after
1,000 simulations, demonstrated the robustness of the TCMAR
and SCR models. The estimated parameters, logit function and
bootstrap results of both models are shown in Table 3.
Correlation Between miRNA Expression
and HCV Infection
None of the transplanted patients with positive HCV RNA
developed rejection. Seven of them were treated with direct
antivirals during first year after LT (obtaining sustained viral
response in 6 of them), while one persisted with positive RNA
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FIGURE 4 | ROC curve analysis for discrimination between subclinical rejectors (SCRs) and non-rejectors. The ROC curve analysis for discrimination between
patients with SCR and non-rejectors for each miRNA was evaluated. (A) Pre-transplantation miR-155-5p capacity to discriminate between SCR and non-rejectors:
AUC = 0.942 (95% CI = 0.886–0.999) and cut-off value = 0.06 (100% sensitivity, 75.3% specificity, PPV = 57% and NPV = 100%); (B) pre-transplantation
miR-181a-5p capacity to discriminate between SCR and non-rejectors: AUC = 0.826 (95% CI=0.640–1.000) and cut-off value=0.457 (80% sensitivity, 87.7%
specificity, PPV=53% and NPV=100%); (C–F) post-transplantation miRNA capacity to discriminate between SCR and non-rejectors: (B) miR-155-5p AUC=0.977
(95% CI = 0.962–0.991) and cut-off value = 0.255 (93.3% sensitivity, 90% specificity, PPV = 89% and NPV = 100%); (C) miR-122-5p: AUC = 0.921
(95% CI = 0.874–0.967) and cut-off value = 2.726 (84% sensitivity, 80% specificity, PPV = 75% and NPV = 90%); (D) miR-181a-5p: AUC = 0.949
(95% CI = 0.910–0.988) and cut-off value=0.587 (91% sensitivity, 80% specificity, PPV = 91% and NPV = 90%); (E) miR-148-3p: AUC = 0.592
(95% CI = 0.505–0.678).
at the end of follow up. We analyzed their miRNA profile
expression, and the results showed no significant differences
with the remaining non-rejector patients (Figure 6). Individuals
with HCV recurrence showed plasma levels of miR-155-5p and
miR-181a-5p below the cut-off values established for the risk of
TCMAR. In the case of miR-122-5p, the results showed a trend
to be higher in the HCV+ group with respect to non-rejectors,
but this difference was not statistically significant (Figure 6C).
However, when we analyzed the miRNA expression individually,
in 3 of 8 HCV+ patients the results showed miR-122-5p plasma
levels above the cut-off value established for the risk of TCMAR
during the period with detectable RNA (Figure 6D). Therefore,
for this specific miRNA, the presence of an active HCV infection
could be a confounding factor for predicting rejection.
DISCUSSION
To our knowledge, this study is the first to monitor the plasma
expression of a panel of miRNAs sequentially in time, pre-
transplantation and over one year post-transplantation (1st week,
day 15th and after the 1st, 2nd, 3rd, 6th, 9th, and 12th month) in
de novo liver recipients. This design provides a better evaluation
of the changes in the expression of the evaluated miRNAs and
its prognostic capacity for the risk of TCMAR. Furthermore, this
study is the first to evaluate a panel of plasmatic miRNAs as a
potential biomarker for the assessment of the risk of SCR in LT.
This study demonstrates that sequential monitoring
of plasmatic miRNA expression levels could reveal useful
prognostic and diagnostic biomarkers for TCMAR and SCR
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FIGURE 5 | Evolution of miR-155-5p, miR-122-5p, and miR-181a-5p expression in patients experiencing subclinical rejection. An example of the evolution of the
miR-155-5p, miR-122-5p, and miR-181a-5p expression in two patients with SCR. The arrow at 3 months post-transplantation indicates the time of the protocol
biopsy. In patient #5, the second arrow indicates the time of the TCMAR episode.
during the post-transplantation period. Specifically, we found
that the plasmatic expression of miR-181a-5p, miR-155-5p, and
miR-122-5p were statistically significant higher in TCMAR and
in SCR patients compared with non-rejectors and could diagnose
and prognostic TCMAR and SCR with high accuracy. However,
no differences in either group of patients were observed for
miR-148-3p expression.
Although the results showed that pre-transplantation, miR-
155-5p expression was significantly higher in rejectors (TCMAR)
and in the SCR group than in non-rejectors, and miR-181a-5p
expression was higher in SCR patients than in non-rejectors,
and the ROC curve analysis showed an excellent AUC value,
the discrete PPV values (∼50%) did not allow for accurately
discriminating patients at risk of suffering clinical events from
false positive cases. However, the method appears capable of
accurately identifying those patients without risk of suffering
TCMAR and SCR, because its NPV was 100%, and as a
consequence, those patients with an expression below the
established cut-off could be candidates to receive IS therapy
that is more moderate, minimizing the adverse effects associated
with treatment.
Post-transplantation, our results showed a significant increase
in the expression of miR-181a-5p, miR-155-5p, and miR-122-
5p in patients who experienced rejection (TCMAR). The AUC
(>0.940), PPV (>70%), and NPV (>95%) values for these
miRNAs were excellent, indicating a very good discriminatory
ability to identify patients at high risk of developing TCMAR.
Our results are in line with previous reports on the potential
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of miRNAs as diagnostic biomarkers of AR (10, 16, 23). In the
case of miR-155-5p, our group demonstrated that this miRNA





(A) TCMAR LOGISTIC REGRESSION MODEL
ß0 −6.35 (9%) −6.65 (−8.17 to −4.52)
ß1 3.87 (14%) 4.16 (1.92 to 5.82)
MOFV 86.324
LOGIT = −6.35 + 3.87 * miR-181a-5p
(B) SRC LOGISTIC REGRESSION MODEL
ß0 −5.18 (9%) −5.31 (−6.29 to −4.07)
ß1 2.27 (33%) 2.28 (0.27 to 4.27)
ß2 1.74 (36%) 1.80 (0.07 to −3.41)
MOFV 153.787
LOGIT = −5.18 + 2.27*miR-181a-5p + 1.74*miR-155-5p
could be a useful prognostic biomarker for the risk of TCMAR
in both liver and renal transplant recipients (8). In the case of
patients with SCR, the results also showed a significant increase
in the expression of miR-155-5p and miR-122-5p, but lower
than that in TCMAR patients, compared with the expression in
patients free of any clinical event. miR-181a-5p expression in the
SCR group reached even higher levels than that in the TCMAR
group from the third month post-transplantation; nevertheless,
these differences disappeared 1 year post-transplantation. Li et al.
demonstrated that the TCR sensitivity and signaling strength
can be modulated by this miRNA and thus may be critical for
regulating the development of effector cell function (25). The
AUC (>0.820), PPV (>70%), and NPV (>90%) values for these
miRNAs were excellent, indicating a very good discriminatory
ability to identify patients at high risk of developing SCR.
The fact that in each TCMAR patient, the individual
expression of miR-181a-5p, miR-155-5p, and miR-122-5p
gradually was upregulated prior to the TCMAR episode (and
earlier than serum transaminases levels were modified during the
FIGURE 6 | Evolution of miR-155-5p, miR-122-5p, and miR-181a-5p expression in patients experiencing the recurrence of HCV+. Differences between patients free
of any clinical event (gray boxes) and HCV+ patients (white boxes) with respect to (A) miR-155-5p; (B) miR-181a-5p and (C) miR-122-5p expression during 1 year
post-transplantation. Five patients developed HCV recurrence after transplantation (n = 3 HCV RNA+ patients until the 3rd month post-transplantation, with exitus
occurring in one of them; one patient, until the 2nd month; and one patient, until the 6th month). Graph (D) shows the individual evolution in miR-122-5p expression in
3 patients with HCV+. The dashed horizontal line indicates the post-transplantation cut-off value for the risk of TCMAR (4.356) with respect to miR-122-5p expression.
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AR) and reached maximum levels at the time of the episode,
clearly shows not only a diagnostic capacity of the miRNAs but
also their potential utility as non-invasive prognostic biomarkers.
Many previous studies have reported a marked elevation of the
transaminase levels in the first hours after liver reperfusion, with
a peak on the 1st or 2nd day after transplantation and, unless
an episode of acute rejection occurs, they are usually normalized
within the first 15 days post-transplantation (34). Therefore,
the elevation of these biochemical parameters during the first
days post-transplantation is not specific for a rejection diagnosis
because there may be other complications that also alter them. It
is important to note that, in our study population, those patients
who showed rejection exhibited an increase in miR-155-5p, miR-
122-5p, and miR-181a-5p expression that was earlier and more
rapid than the increase in serum transaminase levels from the
first weeks post-transplantation. Furthermore, we observed that
in patients with SCR, in contrast to the serum transaminase
levels, which remained within the normal range in all the periods
evaluated, the expression of miR-181a-5p, miR-155-5p, and
miR-122-5p increased progressively from pre-transplantation
to the 3rd month post-transplantation. However, in this case,
the expression levels kept increasing above the cut-off value
established in this study for the risk of TCMAR during the entire
period of the study (1 year post-transplantation), indicating that
an inflammatory process remained without resolving. In fact,
one of these patients ended up experiencing rejection 1 month
after finishing the study. Several renal transplantation studies
have shown that the detection, usually by surveillance biopsies,
of SCR has an impact on the long-term allograft outcome given
that SCR can lead to chronic tubulointerstitial damage, chronic
graft dysfunction, chronic rejection and graft loss (35–37). The
pathways by which persistent inflammation initiates a fibrogenic
response that destroys the renal parenchyma are well-known.
In contrast, the role of SCR in the long-term allograft outcome
in LT is not clear. Recently, Londoño et al. (5) demonstrated
the importance of subclinical inflammatory lesions in long-term
stable LT recipients. The clinical significance of these lesions
and their response to immunosuppressive treatment is currently
uncertain. For this reason, in this context, the clinical utility of
a protocol liver biopsy remains controversial, given that it is
an invasive method that may favor some severe adverse events,
and the benefit that is obtained is not clear; consequently, many
centers do not include this procedure in adult LT programs. If
this clinical entity could be detected by non-invasive biomarkers,
such as the expression of certain miRNAs, the performance of
this type of biopsy could be avoided, which would allow for
the more accurate selection of patients who are truly candidates
for minimizing IS treatment without risk of suffering rejection
and for providing the correct treatment of patients with SCR to
decrease this alloreactivity.
The logistic regression results demonstrated that miR-181a-
5p expression showed a greater prognostic power for the risk
of TCMAR than the individual expression of miR-155-5p or
both miRNAs in combination. On the other hand, to identify
patients at risk of suffering SCR, the model that combined
both miRNAs (miR-181a-5p and miR-155-5p) was more robust
than the model evaluating the expression of each miRNA. It
is evident that a single biomarker may not be sufficient to
reflect all of the complexities associated with LT, and it is
necessary to identify a panel of distinct non-invasive biomarkers
that can detect the degree of alloreactivity of individuals and
diagnose and prognostic graft dysfunction as well as injury.
According to our results for evaluating the risk of TCMAR, the
plasmatic expression of miR-181a-5p (better than that of miR-
155-5p) could be a good candidate for inclusion in this panel of
biomarkers. To identify patients at the risk of suffering SCR, it
would be preferable to include both miRNAs in this panel.
It is important to note that this study evaluated this miRNA
panel in an adult LT population that was practically free of HCV
infection (only 8 patients who presented HCV RNA positivity at
the time of transplantation developed HCV recurrence, and all of
themwere non-rejector patients, with the remaining patients free
of this infection). Therefore, to evaluate the prognostic capacity
of these miRNAs for the risk of TCMAR and SCR, clinical
confounding factors associated with this clinical event can be
discarded. However, it is important to clarify that in HCV+
patients, miR-122-5p expression showed a tendency to be higher
than that in patients free of rejection, and during the period
with active infection, some patients showed levels above the cut-
off value established for the risk of TCMAR. Therefore, for this
specific miRNA, the presence of an active HCV infection could
be a confounding factor to prognostic rejection; in this situation,
there is a requirement to test the HCV viral load to rule out
patients without risk of rejection. Several previous studies have
described significantly elevated serum levels of miR-122-5p in
HCV+ patients (38, 39).
Considering the possible implementation of these biomarkers
in the clinical setting routine, some aspects should be addressed.
Clearly, the following advantages of plasma markers for the
diagnosis and prognosis, in this case, of liver TCMAR or
SCR are obvious: less invasive; involves minimal previous
manipulation of the sample; and less costly compared with the
gold standard method (biopsy). However, there is still more
to learn and discover about miRNAs themselves as well as
their interaction with their target genes, and, on the other
hand, some methodological critical points in the detection of
miRNAs should be resolved to avoid discrepancies between
centers. There is a need for interlaboratory analytical cross-
validation and comprehensive standardization of all analytical
process (e.g., isolation, storage, measurement, and quantification
protocols, the selection of housekeeping genes to correct the
data to normalize the results, etc.). It is necessary to develop
more robust methods and to improve their sensitivity, specificity
and reproducibility as well as to define the cut-off values
for these promising miRNAs in the context of prospective,
randomized, multicenter clinical trials that allow transplant
patient stratification associated with a specific clinical event, such
as TCMAR or SCR.
Because our analysis is only a single-center study,
confirmation by other centers is needed. Furthermore, our
study has some limitations. The event size (TCMAR and SCR)
is small; in fact, this is a limitation common to all studies of this
type of biomarker that has been published to date. It is important
to note that the patients in our hospital were treated with triple
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therapy, and furthermore, this study was the first in which that
the study population was practically free of HCV infection.
Both of these factors surely impact the allograft response and,
consequently, the rate of rejection. However, a large number
of samples was included in the present study, which makes us
confident in our data and strengthens the importance of our
findings because our results still reached significance despite
the small sample size. Furthermore, we have internally validated
the two algorithms obtained after the binary logistic regression
by the bootstrap method, and the results demonstrated the
robustness of both algorithms. The study was performed in a
Caucasian population, and our findings should also be validated
in a separate non-Caucasian population; furthermore, the
absence of patients with antibody-mediated rejection (ABMR) in
our cohort did not allow us to evaluate the prognostic capacity
of these miRNAs for this clinical event. Nevertheless, despite
these limitations, this prospective observational study suggests
that the sequential pre- and post-transplantation monitoring
of the plasma expression of miR-181a-5p, miR-155-5p, and
miR-122-5p may well provide key prognostic biomarkers for
the risk of TCMAR and (for first time evaluated) for the risk
of SCR, and the variation in the level of these miRNAs occurs
earlier and more rapidly than that of serum transaminase
levels. Pre-transplantation, miR-155-5p expression could be
a useful tool to stratify patients at low immunologic risk;
furthermore, post-transplantation, the expression of miR-181a-
5p and miR-155-5p could be candidates for inclusion in an
early, non-invasive prognostic biomarker panel to prevent
TCMAR or SCR.
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